ONCT

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.